The diagnosis of bacterial infections remains a major challenge in medicine. Although numerous contrast agents have been developed to image bacteria, their clinical impact has been minimal because they are unable to detect small numbers of bacteria in vivo, and cannot distinguish infections from other pathologies such as cancer and inflammation [1] [2] [3] [4] [5] [6] [7] . Here, we present a family of contrast agents, termed maltodextrin-based imaging probes (MDPs), which can detect bacteria in vivo with a sensitivity two orders of magnitude higher than previously reported, and can detect bacteria using a bacteria-specific mechanism that is independent of host response and secondary pathologies. MDPs are composed of a fluorescent dye conjugated to maltohexaose, and are rapidly internalized through the bacteria-specific maltodextrin transport pathway [8] [9] [10] [11] , endowing the MDPs with a unique combination of high sensitivity and specificity for bacteria. Here, we show that MDPs selectively accumulate within bacteria at millimolar concentrations, and are a thousand-fold more specific for bacteria than mammalian cells. Furthermore, we demonstrate that MDPs can image as few as 10 5 colony-forming units in vivo and can discriminate between active bacteria and inflammation induced by either lipopolysaccharides or metabolically inactive bacteria.
The diagnosis of bacterial infections remains a major challenge in medicine. Although numerous contrast agents have been developed to image bacteria, their clinical impact has been minimal because they are unable to detect small numbers of bacteria in vivo, and cannot distinguish infections from other pathologies such as cancer and inflammation [1] [2] [3] [4] [5] [6] [7] . Here, we present a family of contrast agents, termed maltodextrin-based imaging probes (MDPs), which can detect bacteria in vivo with a sensitivity two orders of magnitude higher than previously reported, and can detect bacteria using a bacteria-specific mechanism that is independent of host response and secondary pathologies. MDPs are composed of a fluorescent dye conjugated to maltohexaose, and are rapidly internalized through the bacteria-specific maltodextrin transport pathway [8] [9] [10] [11] , endowing the MDPs with a unique combination of high sensitivity and specificity for bacteria. Here, we show that MDPs selectively accumulate within bacteria at millimolar concentrations, and are a thousand-fold more specific for bacteria than mammalian cells. Furthermore, we demonstrate that MDPs can image as few as 10 5 colony-forming units in vivo and can discriminate between active bacteria and inflammation induced by either lipopolysaccharides or metabolically inactive bacteria.
Bacterial infections cause significant mortality and morbidity worldwide despite the availability of antibiotics. For example, in the United States in 2010, bacterial infections caused 40,000 deaths from sepsis alone and were also the leading cause of limb amputations 12, 13 . A major limitation preventing the effective treatment of bacterial infections is an inability to image them in vivo with accuracy and sensitivity. Consequently, bacterial infections can be diagnosed only after they have become systemic or have caused significant anatomical tissue damage, a stage at which they are challenging to treat owing to the high bacterial burden 14, 15 . There is therefore a great need for the development of contrast agents that can image small numbers of bacteria accurately in vivo.
Here we present a family of contrast agents that are robustly internalized through the bacteria-specific maltodextrin transporter and can image bacterial infections in vivo with unprecedented sensitivity and specificity (see Fig. 1 ). Maltohexaose is a major source of glucose for bacteria 16 and MDPs can therefore deliver millimolar concentrations of imaging probes into bacteria, making it possible to image low numbers of bacteria. MDPs also have high specificity for bacteria because mammalian cells do not express the maltodextrin transporter 9 and cannot internalize contrast agents conjugated to maltohexaose. MDPs are composed of α (1-4)-linked glucose oligomers, which are hydrophilic and membrane impermeable 17 ; therefore, MDPs are efficiently cleared from uninfected tissues in vivo, leading to a low background. Furthermore, the lumen of intestinal tissues or the outer layers of the skin are not permeable to glucose oligomers 18 , and MDPs delivered systemically should therefore not be internalized by the resident bacterial microflora present in healthy subjects. These unique properties should allow MDPs to accurately and sensitively image bacteria in vivo.
The bacterial imaging agents MDP-1 and MDP-2 were synthesized to image bacteria in vitro and in vivo, and are composed of maltohexaose conjugated to either perylene or IR786 (see Fig. 2 ). MDP-1 and MDP-2 were synthesized by clicking alkynefunctionalized fluorescent dyes onto an azide-functionalized maltohexaose 19, 20 , which was synthesized from maltohexaose in four steps, following the scheme shown in the Supplementary Information. This synthetic strategy introduces the imaging probes at the anomeric carbon of maltohexaose and was selected because maltodextrin transporters tolerate structural modifications at the reducing end of maltodextrins 21, 22 . A central problem in imaging bacterial infections is to develop targeting strategies that can deliver large quantities of imaging probes to bacteria. This has been challenging because most present imaging probes target the bacterial cell wall and cannot access the bacterial intracellular volume [2] [3] [4] [5] . Maltodextrin transporters, in contrast, internalize their substrates at a robust rate and MDPs should therefore be capable of reaching a high concentration within bacteria. We therefore investigated the uptake of MDP-1 in gram-positive and gram-negative bacteria, under aerobic and anerobic fermentative conditions. Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis and Staphylococcus aureus were incubated with a 20 µM concentration of MDP-1 for 1 h, washed with PBS, lysed, and the MDP-1 in the cellular supernatant was analysed by fluorescence microscopy. Figure 3a demonstrates that MDPs can deliver large quantities of imaging probes to bacteria, under both aerobic and anaerobic fermentative conditions (see Supplementary Fig. S11 ). For example, E. coli internalized MDP-1 at a rate sufficient to generate millimolar intracellular concentrations, and followed Michaelis-Menten kinetics, with a V max of 2.7 nmol min −1 per 10 9 cells and a K M of 1.3 µM (shown in Fig. 3b) knowledge, this represents the first demonstration of a targeting strategy that can deliver millimolar concentrations of an imaging probe to bacteria. We performed experiments with LamB mutant E. coli (LamB mutants) 23 to determine whether MDP-1 was internalized through the maltodextrin transporter. LamB mutants were incubated with MDP-1 and the internalization of MDP-1 was determined following the procedure described above. Figure 3a demonstrates that LamB mutants do not internalize MDP-1 and that, therefore, MDP-1 enters E. coli through the maltodextrin transport pathway. The uptake of MDP-1 in wild-type E. coli could also be inhibited by an excess of maltose or maltohexaose, further confirming that MDP-1 is internalized by maltodextrin transporters (see Supplementary  Fig. S12 ). Finally, we investigated whether metabolically inactive bacteria (azide-treated) internalized MDP-1. Figure 3a shows that metabolically inactive bacteria do not accumulate MDP-1, demonstrating that MDP-1 is not binding to the bacteria cell surface through non-specific interactions. A key challenge in imaging bacteria is to develop probes that have high specificity for bacteria. For example, several present bacterial imaging agents detect bacterial infections using mechanisms that have previously been employed to image inflammation or cancer, and thus lack specificity [1] [2] [3] 5 . Present imaging strategies therefore have a high rate of false positives and require an invasive biopsy for verification. In contrast, MDPs have the potential to image bacteria with high specificity because mammalian cells do not express maltodextrin transporters 9 . MDPs should also have low levels of non-specific uptake in mammalian cells because they are hydrophilic and cannot pentrate the membrane 17 . We therefore investigated the specificity of MDPs towards bacteria. The uptake of MDPs in bacteria and mammalian cells was determined and compared. Bacteria (E. coli, P. aeruginosa, B. subtilis and S. aureus) and mammalian cells (rat aortic smooth muscle cells, macrophages and fibroblasts) were incubated with a 20 µM concentration of MDP-1 for 1 h, washed with PBS, lysed, and the cellular supernatant was analysed for perylene fluorescence signal. Figure 3c shows that MDP-1 has high specificity for bacteria. For example, both gram-positive and gram-negative bacteria internalized MDP-1 at a rate three orders of magnitude faster than mammalian cells. In particular, pathogenic bacteria such as P. aeruginosa and S. aureus internalized 200-300 µmol of MDP-1 per milligram of protein, whereas rat aortic smooth muscle cells and fibroblasts internalized undetectable levels of MDP-1. Furthermore, MDP-2 has a similarly high level of specificity for bacteria when compared with mammalian cells (see Supplementary Fig. S9 ). We found that MDPs have a thousand times better selectivity for bacteria when compared with mammalian cells and should therefore be able to detect bacteria in vivo with high specificity.
We performed experiments to determine whether MDPs could target bacterial biofilms, a major source of pathology from infectious diseases [24] [25] [26] [27] . Although bacterial biofilms have a significantly altered physiology in comparison with planktonic bacteria, they still consume glucose, and therefore can potentially be imaged by MDPs. We therefore investigated the ability of MDP-1 to image bacterial biofilms. Biofilms were incubated with a 20 µM concentration of MDP-1 for 10 min, and counter-stained with SYTO59, a long-wavelength cell-permeable nucleic acid stain. Figure 3d demonstrates that MDP-1 is actively taken up by a wide variety of bacterial biofilms. In particular, biofilms formed from E. coli (12 ± 4 µm thickness), P. aeruginosa (24 ± 15 µm thickness), B. subtilis (16±7 µm thickness) and S. aureus (51±30 µm thickness) all avidly internalized MDP-1, demonstrating that maltodextrin transporters are active in bacterial biofilms and can potentially be used in diagnosing diseases associated with bacterial biofilms. On the basis of these in vitro results we formed a hypothesis that MDPs have the potential to image bacteria in vivo. Accordingly, we investigated the ability of MDP-2 to image bacterial infections in rats. The rats were injected in the left and right thigh muscles, respectively, with E. coli (10 7 colony-forming units, CFUs) and saline (as a control). After 1 h the rats were injected with MDP-2 (280-350 µl of 1 mM MDP-2 in PBS) through the jugular vein and imaged after 16 h in an IVIS imaging machine. Figure 4a shows that MDP-2 can image bacterial infections in vivo. For example, rat thigh muscles infected with E. coli had a 26-fold increase in fluorescence intensity when compared with uninfected controls, allowing the infected area to be easily visualized in vivo. We further quantified the ability of MDP-2 to target bacteria in vivo by performing a biodistribution study of MDP-2 in rats infected with E. coli (10 7 CFUs). Figure 4b demonstrates that MDP-2 accumulates in infected muscle tissues and is efficiently cleared from uninfected muscle, having a 42-fold increase in fluorescence intensity between infected and uninfected muscle tissues. MDP-2 did not accumulate in the bacterial microflora of colon tissue, presumably because of the impermeability of the lumen tissue of intestinal tissues to glucose oligomers 18 . MDP-2 was also efficiently cleared from all the major organs, indicating that it could potentially be used for imaging infections in a wide range of tissues.
We also performed experiments to determine the minimum number of bacteria that could be detected by MDP-2 in vivo. E. coli (10 5 CFUs) were injected into the left rear thigh muscle of rats and imaged with MDP-2 as described above. Finally, we investigated the specificity of MDP-2 for bacteria in vivo. The development of contrast agents that have high specificity for bacteria has been challenging because most contrast agents also accumulate in inflamed and cancerous tissues [1] [2] [3] 5 , owing to their increased metabolic activity and permeability. In contrast, MDP-2 has a thousandfold specificity for bacteria when compared with mammalian cells and clears well from uninfected tissues; therefore, it has the potential to image bacteria with high specificity in vivo. We performed experiments to determine whether MDP-2 could distinguish bacterial infections from both lipopolysaccharide (LPS)-induced inflammation 28 and inflammation induced by metabolically inactive bacteria 29 . We also performed experiments with LamB mutants 23 to determine whether MDP-2 internalization in vivo was occurring by transport through the maltodextrin transporter.
We injected rats with 10 7 CFUs of E. coli in the left thigh muscle and either LPS (1 mg kg −1 ) or metabolically inactive E. coli in the right thigh muscle, and then imaged them using MDP-2 as described above. Figure 5a shows that MDP-2 can distinguish between bacterial infections and inflammation with high specificity. For example, rat thigh muscles infected with E. coli had a 17-fold increase in fluorescence intensity when compared with LPS-treated tissues. Furthermore, MDP-2 did not accumulate in metabolically inactive E. coli (Fig. 5b) , demonstrating that MDP-2 is being actively transported by bacteria in vivo. Finally, we investigated whether MDP-2 was being internalized in vivo through the maltodextrin transporter. LamB mutants (10 7 CFUs) were injected into rats and the uptake of MDP-2 was compared with that for wild-type E. coli, as described above. Figure 5c demonstrates that LamB mutants did not internalize MDP-2, indicating that MDP-2 is transported in vivo through the maltodextrin transport pathway. The uptake of MDP-2 in E. coli could also be inhibited by an excess of maltose in vivo, further confirming that MDP-2 is being internalized by maltodextrin transporters (see Supplementary Fig. S16 ). There is a great need to develop contrast agents that can image bacterial infections with high sensitivity and specificity. In this report we demonstrate that MDPs have a unique combination of robust transport and high specificity, and are able to detect as few as 10 5 CFUs in vivo with high specificity. MDPs have tremendous potential for improving the diagnosis of bacterial infections, given their ability to accurately detect small numbers of bacteria in vivo.
Methods
Synthesis of MDP-1 and MDP-2. See Fig. 2 . MDP-1 and MDP-2 were synthesized by conjugating alkyne-functionalized fluorescent dyes 2 and 3 to azide-functionalized maltohexaose 1, using the click reaction. The synthesis and characterization of the intermediates 1, 2 and 3 are described in the Supplementary Information. The details of the click reaction between 1 and 3 used to generate MDP-2 are described below. The compounds 1 (57.0 mg, 0.03 mmol) and 3 (39.0 mg, 0.06 mmol) were dissolved in DMF (5 ml), to which was added CuI (0.6 mg, 3.0 µmol) and DIPEA (1.2 mg, 0.01 mmol). The mixture was stirred at room temperature for 24 h under nitrogen and the solvent was removed in vacuo. The residue was redissolved in CH 2 Cl 2 (20 ml) and washed with water (5 ml) and brine (5 ml). The organic phase was dried over Na 2 SO 4 , filtered and evaporated to dryness in vacuo. Uptake of MDP-1 and MDP-2 in vitro. Uptake of MDP-1 and MDP-2 in bacteria ( Fig. 3 and Supplementary Fig. S9, respectively) .
The uptake of MDP-1 and MDP-2 was investigated in E. coli (ATCC 33456), P. aeruginosa (ATCC 47085), B. subtilis (ATCC 23059), S. aureus (ATCC 6538), metabolically inactive E. coli (sodium azide-treated, see details in the Supplementary Information) and two E. coli mutant strains, which contained either a LamB mutation (JW3992-1) or a MalE mutation (TL212; ref. 30 ). All bacteria were cultured overnight in Luria-Bertani medium at 37 • C under 5% CO 2 in an incubator shaker (Innova 4230, New Brunswick Scientific). Bacteria (100 µl from the overnight culture) were re-suspended in 30 ml fresh Luria-Bertani medium and cultured to an attenuance D 600nm = 0.5 in a 250 ml flask in an incubator shaker. Bacteria (3 ml) at steady-state growth were transferred into six-well plates and incubated with 20 µM MDP-1 or MDP-2 in Luria-Bertani medium in an incubator shaker at 37 • C for 1 h. The bacteria were centrifuged at 10,000 r.p.m. for 15 min in 15 ml centrifuge tubes, using a Microfuge 18 centrifuge (Beckman Coulter). The recovered bacterial pellets were washed three times with 10 ml PBS. The bacteria were lysed in 2 ml deionized water by sonication with a Branson Sonifier S-250A (Branson Ultrasonics Corporation), using a constant duty cycle at a 200 W output; 10 sonication cycles were performed. The bacterial supernatant (diluted in a 2 ml LETTERS volume) was isolated by centrifuging at 10,000 r.p.m. for 10 min. The fluorescence intensity of the supernatant was measured in a Shimadzu spectrofluorometer (RF 5301PC) and normalized to either the bacterial protein content or the bacterial cell volume. See Supplementary Information for detailed procedures.
Uptake of MDP-1 in bacterial biofilms. See Fig. 3d . The uptake of MDP-1 in bacterial biofilms is described in the Supplementary Information.
In vivo imaging of bacterial infections with MDP-2. In vivo imaging of 10
5 -10 7 bacterial CFUs (Fig. 4 and Supplementary Fig. S14 ). Female Wistar rats (10 weeks, 200-250 g, Harlan Laboratories) were anaesthetized with isofluorane and the hair on the thigh and back was removed. A suspension of E. coli (10 5 -10 7 CFUs) in 250 µL saline was injected into the left rear thigh muscle (injection depth 5 mm), and 250 µL of saline was injected into right rear thigh muscle as a control (injection depth 5 mm). After 1 h the rats were injected with MDP-2 (280-350 µL of 1 mM MDP-2 in PBS) through the jugular vein. Fluorescence images were captured using an IVIS Lumina Imaging System (Caliper Life Sciences) 16 h after the MDP-2 injection. The fluorescence intensity from the bacteria or saline injection area (region of interest) was integrated. At the end of the imaging procedure rats were euthanized, by CO 2 inhalation, and the bacterial infected and saline-treated muscles were collected and analysed by histology for the presence of bacteria. See Supplementary Information for detailed procedures. Six rats were used for each experimental group. Animal protocol. All animal studies were conducted under an animal protocol that was approved by the Animal Use and Care Committee of the Georgia Institute of Technology (IACUC # A10041).
